Literature DB >> 29093097

Analysis of Epstein-Barr Virus Genomes and Expression Profiles in Gastric Adenocarcinoma.

Lori Frappier1, Vincent Ferretti2, Ivan Borozan3, Marc Zapatka4.   

Abstract

Epstein-Barr virus (EBV) is a causative agent of a variety of lymphomas, nasopharyngeal carcinoma (NPC), and ∼9% of gastric carcinomas (GCs). An important question is whether particular EBV variants are more oncogenic than others, but conclusions are currently hampered by the lack of sequenced EBV genomes. Here, we contribute to this question by mining whole-genome sequences of 201 GCs to identify 13 EBV-positive GCs and by assembling 13 new EBV genome sequences, almost doubling the number of available GC-derived EBV genome sequences and providing the first non-Asian EBV genome sequences from GC. Whole-genome sequence comparisons of all EBV isolates sequenced to date (85 from tumors and 57 from healthy individuals) showed that most GC and NPC EBV isolates were closely related although American Caucasian GC samples were more distant, suggesting a geographical component. However, EBV GC isolates were found to contain some consistent changes in protein sequences regardless of geographical origin. In addition, transcriptome data available for eight of the EBV-positive GCs were analyzed to determine which EBV genes are expressed in GC. In addition to the expected latency proteins (EBNA1, LMP1, and LMP2A), specific subsets of lytic genes were consistently expressed that did not reflect a typical lytic or abortive lytic infection, suggesting a novel mechanism of EBV gene regulation in the context of GC. These results are consistent with a model in which a combination of specific latent and lytic EBV proteins promotes tumorigenesis.IMPORTANCE Epstein-Barr virus (EBV) is a widespread virus that causes cancer, including gastric carcinoma (GC), in a small subset of individuals. An important question is whether particular EBV variants are more cancer associated than others, but more EBV sequences are required to address this question. Here, we have generated 13 new EBV genome sequences from GC, almost doubling the number of EBV sequences from GC isolates and providing the first EBV sequences from non-Asian GC. We further identify sequence changes in some EBV proteins common to GC isolates. In addition, gene expression analysis of eight of the EBV-positive GCs showed consistent expression of both the expected latency proteins and a subset of lytic proteins that was not consistent with typical lytic or abortive lytic expression. These results suggest that novel mechanisms activate expression of some EBV lytic proteins and that their expression may contribute to oncogenesis.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Epstein-Barr virus lytic proteins; gastric cancer; transcriptome; whole-genome sequencing

Mesh:

Substances:

Year:  2018        PMID: 29093097      PMCID: PMC5752941          DOI: 10.1128/JVI.01239-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.

Authors:  M Scheffner; K Münger; J C Byrne; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

2.  FastTree 2--approximately maximum-likelihood trees for large alignments.

Authors:  Morgan N Price; Paramvir S Dehal; Adam P Arkin
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

3.  Fast gapped-read alignment with Bowtie 2.

Authors:  Ben Langmead; Steven L Salzberg
Journal:  Nat Methods       Date:  2012-03-04       Impact factor: 28.547

Review 4.  Patho-epigenetics of Infectious Diseases Caused by Intracellular Bacteria.

Authors:  Hans Helmut Niller; Janos Minarovits
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

5.  The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase.

Authors:  Patrick S Beisser; Dennis Verzijl; Yvonne K Gruijthuijsen; Erik Beuken; Martine J Smit; Rob Leurs; Cathrien A Bruggeman; Cornelis Vink
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.

Authors:  Laura L Quinn; Jianmin Zuo; Rachel J M Abbott; Claire Shannon-Lowe; Rosemary J Tierney; Andrew D Hislop; Martin Rowe
Journal:  PLoS Pathog       Date:  2014-08-21       Impact factor: 6.823

7.  Genome-wide analysis of wild-type Epstein-Barr virus genomes derived from healthy individuals of the 1,000 Genomes Project.

Authors:  Gabriel Santpere; Fleur Darre; Soledad Blanco; Antonio Alcami; Pablo Villoslada; M Mar Albà; Arcadi Navarro
Journal:  Genome Biol Evol       Date:  2014-04       Impact factor: 3.416

8.  CaPSID: a bioinformatics platform for computational pathogen sequence identification in human genomes and transcriptomes.

Authors:  Ivan Borozan; Shane Wilson; Paola Blanchette; Philippe Laflamme; Stuart N Watt; Paul M Krzyzanowski; Fabrice Sircoulomb; Robert Rottapel; Philip E Branton; Vincent Ferretti
Journal:  BMC Bioinformatics       Date:  2012-08-17       Impact factor: 3.169

9.  Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with toll-like receptor signaling.

Authors:  Michiel van Gent; Steven G E Braem; Annemieke de Jong; Nezira Delagic; Janneke G C Peeters; Ingrid G J Boer; Paul N Moynagh; Elisabeth Kremmer; Emmanuel J Wiertz; Huib Ovaa; Bryan D Griffin; Maaike E Ressing
Journal:  PLoS Pathog       Date:  2014-02-20       Impact factor: 6.823

10.  Natural Variation of Epstein-Barr Virus Genes, Proteins, and Primary MicroRNA.

Authors:  Samantha Correia; Anne Palser; Claudio Elgueta Karstegl; Jaap M Middeldorp; Octavia Ramayanti; Jeffrey I Cohen; Allan Hildesheim; Maria Dolores Fellner; Joelle Wiels; Robert E White; Paul Kellam; Paul J Farrell
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

View more
  17 in total

1.  Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.

Authors:  Umama Z Siddiqi; Anup S Vaidya; Xinliu Li; Edyta Marcon; Sai Wah Tsao; Jack Greenblatt; Lori Frappier
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

2.  Epstein-Barr Virus (EBV) Is Mostly Latent and Clonal in Angioimmunoblastic T Cell Lymphoma (AITL).

Authors:  Racha Bahri; François Boyer; Mohamad Adnan Halabi; Alain Chaunavel; Jean Feuillard; Arnaud Jaccard; Sylvie Ranger-Rogez
Journal:  Cancers (Basel)       Date:  2022-06-12       Impact factor: 6.575

3.  Human herpesvirus diversity is altered in HLA class I binding peptides.

Authors:  William H Palmer; Marco Telford; Arcadi Navarro; Gabriel Santpere; Paul J Norman
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-29       Impact factor: 12.779

4.  Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder.

Authors:  Eden M Maloney; Vincent A Busque; Sin Ting Hui; Jiaying Toh; Marcelo Fernandez-Vina; Sheri M Krams; Carlos O Esquivel; Olivia M Martinez
Journal:  JCI Insight       Date:  2020-03-26

5.  A Screen for Epstein-Barr Virus Proteins That Inhibit the DNA Damage Response Reveals a Novel Histone Binding Protein.

Authors:  Ting-Hin Ho; Justine Sitz; Qingtang Shen; Ariane Leblanc-Lacroix; Eric I Campos; Ivan Borozan; Edyta Marcon; Jack Greenblatt; Amelie Fradet-Turcotte; Dong-Yan Jin; Lori Frappier
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

6.  Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma.

Authors:  Lusheng Song; Minkyo Song; M Constanza Camargo; Jennifer Van Duine; Stacy Williams; Yunro Chung; Kyoung-Mee Kim; Jolanta Lissowska; Armands Sivins; Weimin Gao; Kailash Karthikeyan; Jin Park; Marcis Leja; Jeffrey I Cohen; Joshua LaBaer; Ji Qiu; Charles S Rabkin
Journal:  Gastric Cancer       Date:  2021-03-04       Impact factor: 7.701

7.  Epstein-Barr virus BORF2 inhibits cellular APOBEC3B to preserve viral genome integrity.

Authors:  Adam Z Cheng; Jaime Yockteng-Melgar; Matthew C Jarvis; Natasha Malik-Soni; Ivan Borozan; Michael A Carpenter; Jennifer L McCann; Diako Ebrahimi; Nadine M Shaban; Edyta Marcon; Jack Greenblatt; William L Brown; Lori Frappier; Reuben S Harris
Journal:  Nat Microbiol       Date:  2018-11-12       Impact factor: 17.745

8.  A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection.

Authors:  Jillian A Bristol; Reza Djavadian; Emily R Albright; Carrie B Coleman; Makoto Ohashi; Mitchell Hayes; James C Romero-Masters; Elizabeth A Barlow; Paul J Farrell; Rosemary Rochford; Robert F Kalejta; Eric C Johannsen; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2018-07-27       Impact factor: 6.823

Review 9.  The Immunomodulatory Capacity of an Epstein-Barr Virus Abortive Lytic Cycle: Potential Contribution to Viral Tumorigenesis.

Authors:  Abigail Morales-Sánchez; Ezequiel M Fuentes-Panana
Journal:  Cancers (Basel)       Date:  2018-03-30       Impact factor: 6.639

10.  Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality.

Authors:  Sara R Selitsky; David Marron; Lisle E Mose; Joel S Parker; Dirk P Dittmer
Journal:  mSystems       Date:  2018-09-25       Impact factor: 6.496

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.